Strategic medical plans, their objectives and the initiatives that deliver them. Every initiative must trace to an approved objective.
Active plans
Objectives on track / at risk / off track
| Plan | Product | Scope | Lifecycle stage | Period | Status | Version | Owner | Budget planned vs actual | Review date |
|---|---|---|---|---|---|---|---|---|---|
Aurelin Global Medical Plan FY2026 MP-2026-ARL-G | Aurelin | Global | Late clinical development | FY2026 | Cross-functional review | v2 | TFDr. Tomás Ferreira | 46% $880k of $1.9M | 01 Dec 2026 |
| Objective | Product | Owner | Status | Progress | Confidence | Initiatives | Plan |
|---|---|---|---|---|---|---|---|
Map and begin engaging the dermatology KOL landscape in US and EU ahead of Phase III readout. SO-ARL-01 | Aurelin | TFDr. Tomás Ferreira | Not started | 12% | Medium | 1 | Aurelin Global Medical Plan FY2026 |
| Initiative | Type | Product | Objective | Owner | Dates | Status | Priority | Progress | Budget vs spend |
|---|---|---|---|---|---|---|---|---|---|
| Medical strategy initiative | Aurelin | SO-ARL-01 | TFDr. Tomás Ferreira | 01 Sept 2026 – 28 Feb 2027 | Planned | Medium | 10% | $0 / $120k |